New York’s attorney general is dropping an antitrust lawsuit against a drug manufacturer after his office blocked what he alleged was an attempt to force Alzheimer’s patients to switch to a newer patented drug instead of cheaper generic alternatives.
Attorney General Eric Schneiderman and Allergan PLC said Wednesday that they have agreed to resolve the lawsuit filed over the company’s plans to withdraw Namenda, a popular Alzheimer’s treatment, a few months before lower-cost generic drugs became available.
Schneiderman’s office had argued the move was timed to force patients onto a new patented drug Namenda XR instead of the generics.
A federal judge agreed last year, requiring Allergan to continue distributing the older drug until summer 2015, when generic medications entered the market.
“Our lawsuit prevented Allergan from pursuing its plan to block competition, thus preserving patient choice for hundreds of thousands of Alzheimer’s patients, and protecting the public from bearing hundreds of millions’ of dollars in unnecessary drug costs,” Schneiderman said in a statement announcing the resolution of the legal challenge.
The Dublin-based Allergan, previously known as Actavis, confirmed the settlement. The company has agreed to pay $172,000 to cover some of the state’s legal fees.
Full content: Reuters
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Judge Mehta Questions Both Sides in Landmark Google Antitrust Case
May 2, 2024 by
CPI
FCC Urges Urgent Funding for Removal of Chinese Telecom Equipment from U.S. Networks
May 2, 2024 by
CPI
Former Pioneer CEO Facing Potential Criminal Charges For Colluding With OPEC
May 2, 2024 by
CPI
South Korea’s Antitrust Regulator Greenlights K-Pop Powerhouse Deal
May 2, 2024 by
CPI
Exxon’s Pioneer Purchase Approved, Former CEO Barred from Board
May 2, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI